Letter: Enhancing HCC Surveillance–GES Score Represents an Innovative Simple Effective Tool for Risk Stratification, Patient Safety and Reduced Anxiety

We read with interest the article by Shiha et al., titled ‘Individualized HCC Surveillance Using Risk Stratification Scores in Advanced Fibrosis and Cirrhotic HCV Patients Who Achieved SVR: A Prospective Study’ [1].

As a board member of World Hepatitis Alliance representing African region and as a patient who developed cirrhosis, I was fortunate to receive liver transplantation in time following diagnosis of HCC at early stage. I am particularly encouraged by the development of the General Evaluation Score (GES) as a practical, easy to use, bedside and effective tool for stratifying the risk of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV)-related liver cirrhosis. The GES represents a significant advancement in our ability to safely monitor at-risk patients while optimising the allocation of healthcare resources.

This prospective study by Shiha et al. [1] individualised patient surveillance according to the calculated GES is particularly suitable for developing countries with limited healthcare facilities and public health funds.

In high-risk patients, we recognise the critical role of tailored surveillance. By employing more frequent follow-ups, the use of GES facilitates the early detection of HCC, significantly enhancing the efficacy of available treatments. For patients at low risk, shiha et al.'s strategy reduces the frequency of surveillance visits, limiting their exposure to potentially harmful diagnostic procedures, which in turn decreases their anxiety and financial strain. Intermediate-risk patients are monitored according to established guidelines, ensuring they receive appropriate care without unnecessary interventions.

In conclusion, the GES represents a significant advancement in the field of HCC surveillance, particularly for developing countries. Its simplicity, suitability for real-life application and ability to individualise screening plans make it a valuable tool for improving patient outcomes and optimising healthcare resources, while enhancing patient safety and comfort. Therefore, we advocate for its wider validation and adoption in developing countries, particularly across Africa, to support patient organisations and healthcare providers in their efforts to combat HCC effectively.

Ibrahima Gueye: writing – original draft, writing – review and editing.

The author declares no conflicts of interest.

This article is linked to Shiha et al papers. To view these articles, visit https://doi.org/10.1111/apt.18291 and https://doi.org/10.1111/apt.18494.